“天然免疫”启明星 | 泽安生物医药Pre-A+轮融资超千万美元，启明创投领投 | Bilingual

今天，很高兴为大家分享来自市场资讯的启明星 | 泽安生物医药Pre-A+轮融资超千万美元，启明创投领投 | Bilingual，如果您对启明星 | 泽安生物医药Pre-A+轮融资超千万美元，启明创投领投 | Bilingual感兴趣，请往下看。

泽安生物医药（LTZ Therapeutics，下称“LTZ”或“公司”）宣布完成Pre-A+轮融资，融资金额超过千万美元。自2022年成立以来，公司已累计融资近3000万美元。本轮融资由启明创投领投。融资资金将用于系统性验证天然免疫衔接抗体技术平台（Innate Engager Platform），推进多个核心品种的临床前研究、IND申报和早期临床试验，并进一步扩充全球团队。

LTZ是一家聚焦天然免疫细胞（特别是巨噬细胞）和免疫抑制性细胞（例如Treg、CAF）的国际化生物技术公司，正在潜心研发全球第一款广谱的天然免疫细胞多功能衔接抗体平台。该平台技术可以同时调动多种天然免疫细胞（包括巨噬细胞、NK细胞等）作为效应分子，以协同的方式直接杀伤肿瘤细胞或免疫抑制性细胞；并且，通过促进肿瘤微环境中的炎症反应，间接激活适应性免疫（即后天免疫）。这种新型免疫疗法有望全面提升患者的综合临床获益，尤其在实体肿瘤、自身免疫性疾病等领域。

得益于股东们的信任支持和团队成员的戮力同心，LTZ成立一年多以来，在团队建设、创新研发、对外合作等方面进展喜人，包括快速组建了经验丰富的中国、美国及欧洲运营团队，初步构建了技术平台和产品管线，顺利开展多项抗体发现和非临床研究，并与多家顶级肿瘤医院展开反转化医学的合作研究，联合探索肿瘤微环境中的癌症生物学与免疫学。

与此同时，LTZ聘请学术界、产业界、临床界的杰出科学家Sarah Hymowitz博士、Greg Cosma博士、Lukas Amler博士、Lillian Siu博士、Stephen Beers博士和HiroyoshiNishikawa博士，组成世界一流的科学顾问委员会（SAB），协同赋能LTZ的新药研发全流程，在基础研究和临床研究之间形成转化医学与反转化医学双向流动、相得益彰的闭环。

“继一年前完成1700万美元Pre-A轮融资之后，很高兴再次获得知名投资机构注资。衷心感谢所有新、老投资人的高度认可和鼎力支持，”LTZ联合创始人兼首席执行官李金泽博士（Dr. Robert Li）表示，“公司计划今年完成天然免疫衔接多功能抗体平台的临床前验证和首款药物分子的IND-enabling工作，明年年初申报IND，并启动FIH临床研究。身为医药人，我们始终以治病救人为终极目标。为了帮助全球患者早日获得更有效、更安全的原创新药，我们在实现前沿突破、推进临床转化的征途上快马加鞭、日夜兼程。”

启明创投合伙人陈侃博士表示：“LTZ的科学创新十分令人兴奋。公司为血液瘤和实体瘤开发新型天然免疫衔接抗体平台的战略以及所遴选药物分子的临床前验证结果极具潜力，尤其是通过新颖的受体和方式有效衔接和激活巨噬细胞。这将有机会深刻影响中国乃至世界范围内免疫治疗的战略方向。”

本轮融资由启明创投领投，顺为资本、力合泓鑫参与投资，老股东险峰旗云追加投资。

LTZ Announces over $10 Million Pre-A+ Financing led by Qiming Venture Partners

LTZTherapeutics – an immunotherapy-focusedbiotech company – today announced it has raised over $10million in pre-A+ financing led by Qiming Venture Partners. The closing of this round brings LTZ's total funding to approximately $30 millionsince the company was founded in 2022. The proceeds from this round of fundingwill be used to continue establishing the company's platform and pipeline and buildingLTZ's global operations team.

"LTZ has made significantprogress, both scientifically and operationally, since it was established lastyear," said Robert Li Ph.D, Co-Founder and CEO of LTZ. "We plan to capitalizeon our progress by advancing the company's lead molecule to its FIH clinical trial in early 2024, completing preclinical validation work of ourinnate engager platform and continuing to advance other molecules in thecompany's portfolio and build our global team. Furthermore,we're grateful for our scientific team and advisoryboard as well as the support from our syndicate of investors who acknowledgethe exceptional value of our platform and pipeline."

With the addition of three new members, there is now a total of sixscientific board members. Joining Sarah HymowitzPh.D, Greg Cosma Ph.D and Lukas Amler Ph.D, new members include Lillian L Siu,MD, Stephen Beers Ph.D and Hiroyoshi Nishikawa, MD, Ph.D.

"LTZ's strategy to develop a novel Innate Engager Platform for bothhematological malignancy and solid tumors as well as its preclinical validationwork of selected constructs is extremely promising. This approach could have profound impact on thefuture of immunotherapy development inChina and globally," said Kan Chen Ph.D, Partner at Qiming Venture Partners.

Additionally, external research collaborations with top-tiercancer hospitals have also been established to support the company's reversetranslational studies – to better understand the cancer biology and immunology in tumor microenvironment.

This financing was led by Qiming Venture Partners, with co-investor participation from Shunwei Capital, Lihehongxin Venture Capital Partnership and K2 Venture Partners.

好了，关于启明星 | 泽安生物医药Pre-A+轮融资超千万美元，启明创投领投 | Bilingual就讲到这。